Jeffrey J. Kraws
Mr. Kraws was appointed independent, non-executive Chairman of Synthetic Biologics' Board in May 2012. Since 2003, Mr. Kraws has served as Chief Executive Officer and co-founder of Crystal Research Associates, and since February 2012, he has served as partner and co-founder of TopHat Capital, LLC. Mr. Kraws has also served as President of Ra Medical Systems since August 2016. Well known and respected on Wall Street, Mr. Kraws has received some of the most prestigious awards in the industry. Among other awards, he was given a "5-Star Rating" in 2001 by Zacks and was ranked the number one analyst among all pharmaceutical analysts for stock performance in 2001 by Starmine.com. Prior to founding Crystal Research Associates, Mr. Kraws served as co-president of The Investor Relations Group (IRG), a firm representing primarily under-followed, small-capitalization companies. Previously, Mr. Kraws served as a managing director of healthcare research for Ryan Beck & Co. and as director of research/senior pharmaceutical analyst and managing director at Gruntal & Co., LLC (prior to its merger with Ryan Beck & Company). Mr. Kraws served as managing director of the healthcare research group and senior pharmaceutical analyst at First Union Securities (formerly EVEREN Securities); as senior U.S. pharmaceutical analyst for the Swedish-Swiss conglomerate Asea Brown Boveri; and as managing director and president of the Brokerage/Investment Banking operation of ABB Aros Securities, Inc. He also served as senior pharmaceutical analyst at Nationsbanc Montgomery Securities, BT Alex Brown & Sons, and Buckingham Research. Mr. Kraws also has industry experience, having been responsible for competitive analysis within the treasury group at Bristol-Myers-Squibb Company. He holds an MBA from Cornell University and a BS degree from State University of New York-Buffalo.
Jeffrey Wolf, JD
Mr. Wolf has substantial experience in creating, financing, nurturing and growing new ventures based upon breakthrough research and technology. In 2008, he founded Heat Biologics, Inc., a publicly traded company engaged in the research and development of drugs focused on cambating cancer and other diseases, and has served as its Chief Executive Officer since April 2010. Mr. Wolf is the founding partner of Seed-One Ventures, LLC, a venture capital group focused on seed-stage technology-based investments. Mr. Wolf has been a founder of Elusys Therapeutics, Inc., an antibody-based therapeutic company, Tyrx Pharma, Inc., a biopolymer-based company, Sensatex, Inc., a medical device company and Generation Mobile, Inc. a telecommunications company. Prior to founding Seed-One Ventures, Mr. Wolf served as the Managing Director of The Castle Group, Ltd., a biomedical venture capital firm. At both organizations, Mr. Wolf was responsible for supervising the formation and funding of new technology, biomedical, and service oriented ventures. Mr. Wolf currently sits on the board of Heat Biologics, Inc. (NASDAQ: HTBX) and Elusys Therapeutics. Mr. Wolf received an MBA from Stanford Business School, a JD from New York University School of Law and a BA with honors in Economics from the University of Chicago.
Chief Executive Officer, Chief Financial Officer, Treasurer and Secretary, Director
Mr. Shallcross has been a member of our Board of Directors since December 6, 2018 and currently serves as our Chief Executive Officer, a position he was appointed to on December 6, 2018, and our Chief Financial Officer. Mr. Shallcross was appointed as our Interim Chief Executive Officer on December 5, 2017 and has served as our Chief Financial Officer, Treasurer and Secretary since joining us in June 2015. Mr. Shallcross brings to our company operational, financial and international biotech industry experience, as well as an established track record at leading the financial development and strategy for several publicly traded biotech companies. From May 2013 through May 2015, Mr. Shallcross served as Executive Vice President and Chief Financial Officer of Nuo Therapeutics, Inc. (formerly Cytomedix, Inc.). In January 2016, Nuo Therapeutics, Inc. filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and on April 25, 2016, the Bankruptcy Court entered an order granting approval of Nuo’s plan of reorganization. From July 2012 to May 2013, Mr. Shallcross held the offices of Executive Vice President, Chief Financial Officer and Treasurer of Empire Petroleum Partners, LLC, a motor fuel distribution company. From July 2011 to March 2012, Mr. Shallcross was Acting Chief Financial Officer of Senseonics, a privately-held medical device company located in Germantown, MD. From January 2009 to March 2011, he served as Executive Vice President and Chief Financial Officer of Innocoll AG (formerly privately held Innocoll Holdings, Inc.), a global, commercial-stage biopharmaceutical company specializing in the development and commercialization of collagen-based products. He also served for four years as the Chief Financial Officer and Treasurer of Vanda Pharmaceuticals, Inc., leading the company through its successful IPO and follow-on offering and previously served as the Senior Vice President and Chief Financial Officer of Middlebrook Pharmaceuticals, Inc. (formerly Advancis Pharmaceutical Corporation). In addition, Mr. Shallcross also served as the Chief Financial Officer of Bering Truck Corporation. Mr. Shallcross has served as a director of Newgioco Group, Inc., a public traded company, since June 2019. He holds an MBA from the University of Chicago’s Booth School of Business, a Bachelor of Science degree in Accounting from the University of Illinois, Chicago, and is a Certified Public Accountant in the State of Illinois.
John Monahan, Ph.D.
Dr. John Monahan served as Executive Vice President, Research & Development, at Synthetic Biologics from December 2011 until December 2015. Dr. Monahan is an experienced CEO-level executive of biotech companies focused on gene medicine and pharmaceutical companies with biotechnology research departments. He is currently also a board member of a number of private biotech companies. In 1992, he founded and built Avigen, Inc., a biotech company that pioneered and led the development of gene medicines based on AAV vectors, now an industry standard. Over a 12 year period as CEO of Avigen, Dr. Monahan took the company public through its IPO, raised over $235 million and led the company through a number of gene medicine Investigational New Drug (IND) applications. Prior to founding Avigen, Dr. Monahan served as Vice President - Research and Development at Somatix, another pioneering gene medicine company, Prior to that he was Director of Molecular & Cell Biology at Triton Biosciences (since merged with Berlex Laboratories). Prior to that he was Research Group Chief, Department of Molecular Genetics at Hoffmann-LaRoche, Inc. and Adjunct Assistant Professor, Department of Cell Biology at New York University. He earned a PhD in Biochemistry from McMaster University, Hamilton, Canada and a BS degree in Science from University College, Dublin, Ireland. Dr. Monahan has over 50 publications/reviews in the scientific literature and has made hundreds of presentations including public TV interviews, to scientific groups, investors and the public in general over the years.